Ag/IgG ICs have been shown to allow cross-priming of tumor-specific CD8+ T cells able to protect against the development of colorectal cancer and lung metastases, by a process involving the surface FcγR and cytoplasmic FcRn (neonatal Fc receptor for IgG) of DC. The gene discussed is FCGR2A; the disease is neoplasm.